STW 5 is effective against nonsteroidal anti-inflammatory drugs induced gastro-duodenal lesions in rats.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
21 Oct 2019
Historique:
received: 28 04 2019
revised: 16 08 2019
accepted: 13 09 2019
entrez: 30 10 2019
pubmed: 30 10 2019
medline: 27 2 2020
Statut: ppublish

Résumé

Proton pump inhibitors are often used to prevent gastro-intestinal lesions induced by nonsteroidal anti-inflammatory drugs. However, they are not always effective against both gastric and duodenal lesions and their use is not devoid of side effects. To explore the mechanisms mediating the clinical efficacy of STW 5 in gastro-duodenal lesions induced by nonsteroidal anti-inflammatory drugs (NSAIDs), exemplified here by diclofenac, in a comparison to omeprazole. Gastro-duodenal lesions were induced in rats by oral administration of diclofenac (5 mg/kg) for 6 successive days. One group was given concurrently STW 5 (5 mL/kg) while another was given omeprazole (20 mg/kg). A day later, animals were sacrificed, stomach and duodenum excised and divided into 2 segments: One for histological examination and one for measuring inflammatory mediators (tumor necrosis factor α, interleukins-1β and 10), oxidative stress enzyme (heme oxygenase-1) and apoptosis regulator (B-cell lymphoma 2). Diclofenac caused overt histological damage in both tissues, associated with parallel changes in all parameters measured. STW 5 and omeprazole effectively prevented these changes, but STW 5 superseded omeprazole in protecting against histological damage, particularly in the duodenum. The findings support the therapeutic usefulness of STW 5 and its superiority over omeprazole as adjuvant therapy to NSAIDs to protect against their possible gastro-duodenal side effects.

Sections du résumé

BACKGROUND BACKGROUND
Proton pump inhibitors are often used to prevent gastro-intestinal lesions induced by nonsteroidal anti-inflammatory drugs. However, they are not always effective against both gastric and duodenal lesions and their use is not devoid of side effects.
AIM OBJECTIVE
To explore the mechanisms mediating the clinical efficacy of STW 5 in gastro-duodenal lesions induced by nonsteroidal anti-inflammatory drugs (NSAIDs), exemplified here by diclofenac, in a comparison to omeprazole.
METHODS METHODS
Gastro-duodenal lesions were induced in rats by oral administration of diclofenac (5 mg/kg) for 6 successive days. One group was given concurrently STW 5 (5 mL/kg) while another was given omeprazole (20 mg/kg). A day later, animals were sacrificed, stomach and duodenum excised and divided into 2 segments: One for histological examination and one for measuring inflammatory mediators (tumor necrosis factor α, interleukins-1β and 10), oxidative stress enzyme (heme oxygenase-1) and apoptosis regulator (B-cell lymphoma 2).
RESULTS RESULTS
Diclofenac caused overt histological damage in both tissues, associated with parallel changes in all parameters measured. STW 5 and omeprazole effectively prevented these changes, but STW 5 superseded omeprazole in protecting against histological damage, particularly in the duodenum.
CONCLUSION CONCLUSIONS
The findings support the therapeutic usefulness of STW 5 and its superiority over omeprazole as adjuvant therapy to NSAIDs to protect against their possible gastro-duodenal side effects.

Identifiants

pubmed: 31660030
doi: 10.3748/wjg.v25.i39.5926
pmc: PMC6815791
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Plant Extracts 0
Protective Agents 0
iberogast 0
Diclofenac 144O8QL0L1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5926-5935

Informations de copyright

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: Mohamed T Khayyal reports grants from Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, during the conduct of the study; Olaf Kelber, Ramy M. Ammar, Heba Abdel-Aziz are employed by Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany; all other authors have no conflict of interest.

Références

Fortschr Med. 1987 Apr 25;105(12):239-42
pubmed: 3297957
Indian J Dent Res. 2009 Oct-Dec;20(4):418-22
pubmed: 20139563
N Engl J Med. 1993 Jan 14;328(2):106-13
pubmed: 8439348
Annu Rev Med. 2000;51:289-98
pubmed: 10774465
Nat Rev Immunol. 2008 Nov;8(11):837-48
pubmed: 18927578
J Pharmacol Sci. 2010;113(2):134-42
pubmed: 20484868
Phytomedicine. 2014 Sep 25;21(11):1390-9
pubmed: 25022208
Life Sci. 2018 Jan 15;193:47-56
pubmed: 29223540
Aliment Pharmacol Ther. 2000 May;14(5):535-41
pubmed: 10792115
Cell Stress Chaperones. 2003 Winter;8(4):329-34
pubmed: 15115285
Neurogastroenterol Motil. 2014 Jul;26(7):893-900
pubmed: 24965903
World J Gastroenterol. 2011 Oct 14;17(38):4283-8
pubmed: 22090784
Aliment Pharmacol Ther. 1998 Feb;12(2):135-40
pubmed: 9692687
Lancet. 2010 Jul 17;376(9736):173-9
pubmed: 20638563
Front Pharmacol. 2016 Oct 26;7:393
pubmed: 27833553
Int J Colorectal Dis. 2004 Jul;19(4):308-15
pubmed: 14605835
J Appl Toxicol. 2017 Jan;37(1):71-83
pubmed: 27652576
Gastroenterol Jpn. 1987 Aug;22(4):413-8
pubmed: 3666382
Cancer Res. 2006 Dec 15;66(24):11580-4
pubmed: 17178849
Phytomedicine. 2006;13 Suppl 5:56-66
pubmed: 16963243
Dig Dis. 2017;35 Suppl 1:25-29
pubmed: 29421817
Aliment Pharmacol Ther. 2009 Sep 15;30(6):517-31
pubmed: 19575764
J Nutr. 1996 Oct;126(10):2519-30
pubmed: 8857513
N Engl J Med. 1998 Mar 12;338(11):727-34
pubmed: 9494149
Cytokine. 2007 Mar;37(3):236-45
pubmed: 17517520
Int J Colorectal Dis. 2012 Nov;27(11):1445-53
pubmed: 22562255
Chem Biol Interact. 2007 Apr 5;167(1):71-83
pubmed: 17327128
Curr Pharm Des. 2003;9(30):2541-51
pubmed: 14529552
Int J Colorectal Dis. 2007 Jun;22(6):591-9
pubmed: 17124609
J Pediatr Gastroenterol Nutr. 2012 Apr;54(4):471-6
pubmed: 21873894
Phytomedicine. 2006;13 Suppl 5:114-21
pubmed: 16978851
Aust Prescr. 2017 Jun;40(3):91-93
pubmed: 28798512
Gastroenterology. 2016 May;150(6):1380-92
pubmed: 27147122

Auteurs

Mohamed T Khayyal (MT)

Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt. mtkhayyal@gmail.com.

Walaa Wadie (W)

Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

Enas A Abd El-Haleim (EA)

Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

Kawkab A Ahmed (KA)

Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Cairo 12211, Egypt.

Olaf Kelber (O)

Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt 64295, Germany.

Ramy M Ammar (RM)

Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt 64295, Germany.

Heba Abdel-Aziz (H)

Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt 64295, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH